You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 860 CD40 agonism is required to promote the function of cross-presenting dendritic cells and increase triple negative breast cancer response to radiation and CTLA4 inhibition

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
860 CD40 agonism is required to promote the function of cross-presenting dendritic cells and increase triple negative breast cancer response to radiation and CTLA4 inhibition

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Charpentier M, Rudqvist N, Spada S, et al
860 CD40 agonism is required to promote the function of cross-presenting dendritic cells and increase triple negative breast cancer response to radiation and CTLA4 inhibition
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0860